Vivos (RDGL) Capital Expenditures (2010 - 2017)

Vivos' (RDGL) quarterly Capital Expenditures came in at $2800.0 in Q1 2017, down 71.29% quarter-over-quarter from $9754.0 in Q1 2013.

Vivos (RDGL) Capital Expenditures (2010 - 2017) Analysis & Trends

Vivos has disclosed Capital Expenditures across 4 years of filings, most recently posting $2800.0 for Q1 2017.

Capital Expenditures for Q1 2017 came in at $2800.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2017 was -$72124.0 (changed N/A YoY), and the FY2025 annual result was $103185.0, changed N/A from the prior year.
Capital Expenditures came in at $2800.0 for Q1 2017 at Vivos, down from $9754.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $9754.0 in Q1 2013 to a low of $2800.0 in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	399.00 Mn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	166.00 Mn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	444.00 Mn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	64.90 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-85.46 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	76.60 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	86.00 Mn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	90.20 Mn
10	Vivos	-	-	-3,105.00	-

Download Data